| 生物活性 |
Vasculotide is a blood-brain barrier (BBB)-penetrating Tie2 activator that binds to a unique domain of Tie2, inducing receptor clustering to drive phosphorylation, activating downstream PI3K/Akt and eNOS pathways, enhancing interendothelial junctions (VE-cadherin, claudin-5, etc.), and inhibiting inflammatory adhesion molecules, ultimately stabilizing the vascular endothelial barrier and reducing permeability, while also alleviating cardiopulmonary bypass-induced pulmonary microvascular leakage and microcirculatory disturbance, serving as a radiotherapeutic adjuvant protective agent to reduce acute radiation dermatitis, promoting BBB recovery after focused ultrasound (FUS), and attenuating lung injury in combination with antibiotics. |
体内研究 (In Vivo) |
Vasculotide (200 ng/只;静脉注射;单剂量) 可在心肺转流术期间及术后保留雄性 Wistar 大鼠的微循环灌注,并减少其肺血管渗漏,且不会改变内源性血管生成素/Tie2 系统。 Vasculotide (10 μg/kg;腹腔注射;照射前 24 h 和 1.5 h 给药,之后每隔 1 天给药 1 次,持续 28 天) 可减轻小鼠急性皮肤辐射损伤,具体表现为重度脱屑伤口总面积减少 43%、炎症反应减轻以及伤口愈合情况改善。 Vasculotide (10 μg/kg;腹腔注射;仅照射前、持续给药、仅照射后;共 26 天) 经所有受试给药方案 (照射前、持续给药、照射后) 给药后,可减轻接受 35 Gy 照射小鼠的急性皮肤辐射损伤,其中照射后给药方案可使总体皮肤损伤评分显著降低 28%。 Vasculotide (250 ng;腹腔注射;每 48 小时 1 次;持续 3 个月) 可使 TgCRND8 小鼠中聚焦超声 (FUS) 诱导血脑屏障 (BBB) 通透性的超谐波阈值压力降低 21-29%,并加速 BBB 修复,在该阿尔茨海默病模型中,FUS 处理后 20 小时 BBB 闭合率可达 87%。 Vasculotide (500 ng;静脉注射;2 次给药) 联合 Ampicillin (MS-V19309) 的辅助治疗可显著降低机械通气肺炎链球菌肺炎小鼠的肺通透性、呼吸机相关性肺损伤 (VILI) 相关组织学损伤及水肿形成,且不影响免疫应答或细菌载量。
| Animal Model: |
Wistar (male, 375-425 g) |
| Dosage: |
200 ng |
| Administration: |
i.v.; single dose |
| Result: |
Completely preserved microcirculatory perfusion during and after CPB, with the number of continuously perfused and non-perfused vessels remaining stable throughout the experiment. Significantly reduced Evans blue dye extravasation in lung tissue compared with untreated CPB rats. Did not significantly reduce leakage in kidney tissue. Did not affect circulating concentrations of angiopoietin-1, angiopoietin-2, or soluble Tie2. Did not affect angiopoietin-1, angiopoietin-2, or Tie2 gene/protein expression in kidney or lung tissue, or endothelial adhesion molecule expression compared with untreated CPB rats. |
| Animal Model: |
athymic nude mice (7-week-old female) |
| Dosage: |
10 μg/kg |
| Administration: |
i.p.; 24 h and 1.5 h before irradiation, then every other day; 28 days |
| Result: |
Reduced skin damage scores on day 6 and day 8, with no significant difference in overall area under the curve. Reduced mean severe desquamation wound area overall, with peak areas reduced on day 12 and day 14. Reduced weight loss 2 days post-irradiation, with full weight recovery by day 28. Lowered oxygenated hemoglobin (oxyHb) levels overall, with trends toward lower levels on day 5, day 9, and day 12. Reduced myeloperoxidase bioluminescence signal 6.4-fold lower than PBS at 72 h post-irradiation, and reduced neutrophil counts in skin sections on day 5. Reduced serum MIP-2/CXCL2 levels on day 5 post-irradiation. Increased CD31+ microvascular endothelial cell staining-to-area ratio on day 14 post-irradiation, with no significant difference in CD45+ leukocyte staining. Reduced ulcerated wounds by day 28 post-irradiation (1 of 5 vs. 4 of 5 in PBS group), with histological evidence of better healing. |
| Animal Model: |
athymic nude mice (7-week-old female) |
| Dosage: |
10 μg/kg |
| Administration: |
i.p.; pre-irradiation only (24 h and 1.5 h before irradiation); continuous (24 h and 1.5 h before irradiation, then every other day); post-irradiation only (starting 2 days after irradiation, then every other day); 26 days |
| Result: |
Reduced overall skin damage scores with post-irradiation treatment, with higher body weight by day 26 and significantly reduced myeloperoxidase bioluminescence on day 23 post-irradiation. Reduced total wound size overall with pre-irradiation, continuous, and post-irradiation treatments. |
| Animal Model: |
Mixed C57/C3H background (male and female, 3 months old at study start; transgenic TgCRND8 with double amyloid precursor protein mutations KM670/671NL, V717F; non-transgenic littermate controls) |
| Dosage: |
250 ng |
| Administration: |
i.p.; every 48 hours; 3 months |
| Result: |
Reduced the ultra-harmonic threshold pressure for FUS-induced BBB permeability by 21-29% compared to all other groups. Did not alter initial gadolinium enhancement post-FUS in either TgCRND8 or non-transgenic mice. Accelerated BBB closure in TgCRND8 mice: at 6, 12, and 20 hours post-FUS, 26%, 17%, and 13% of focal spots remained permeable to gadolinium, respectively, leading to 87% BBB closure by 20 hours. Resulted in 61%, 26%, and 26% of focal spots remaining permeable to gadolinium at 6, 12, and 20 hours post-FUS in non-transgenic mice, respectively, leading to 74% BBB closure by 20 hours. Showed a statistically significant difference in BBB closure rate between Vasculotide-treated and PBS-treated TgCRND8 mice via log-rank analysis. Led to no detectable Evans blue dye in the brain at 24 hours post-FUS in both Vasculotide-treated TgCRND8 and non-transgenic mice, indicating complete BBB impermeability. |
| Animal Model: |
C57BL/6N (female, 8-10 weeks old, 18-20 g, intranasal inoculation with 5 × 106 CFU Streptococcus pneumoniae serotype 3 followed by 6 hours of mechanical ventilation starting 24 hours post-infection) |
| Dosage: |
500 ng (first dose); 500 ng (second dose) |
| Administration: |
i.v.; 2 doses (22 hours post-infection, 1.5 hours prior to experiment termination) |
| Result: |
Significantly reduced pulmonary hyperpermeability (measured as HSA BALF/plasma ratio) compared to ampicillin monotherapy. Reduced the percentage of lung area affected by VILI compared to ampicillin monotherapy or untreated mice. Reduced VILI severity scores compared to ampicillin monotherapy or untreated mice. Diminished alveolar edema formation in VILI-affected lung areas compared to ampicillin monotherapy or untreated mice. Reduced perivascular edema formation in pneumonia-affected lung areas compared to ampicillin monotherapy or untreated mice. Did not alter pulmonary or systemic leukocyte counts, cytokine/chemokine production, local or systemic bacterial burden, pulmonary Tie2 mRNA expression, or pulmonary Tie2 phosphorylation. |
|